Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options

This article was originally published in The Pink Sheet Daily

Executive Summary

UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost

You may also be interested in...



Price Discount Paves The Way For NICE To Clear GSK’s Revolade

U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.

With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder

Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.

With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder

Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel